First Department of Cardiology, Hippokration General Hospital, National and Kapodistrian University of Athens Medical School, 114 Vasilissis Sofias Avenue, 11527 Athens, Greece
Eleni Manta
First Department of Cardiology, Hippokration General Hospital, National and Kapodistrian University of Athens Medical School, 114 Vasilissis Sofias Avenue, 11527 Athens, Greece
Christos Fragoulis
First Department of Cardiology, Hippokration General Hospital, National and Kapodistrian University of Athens Medical School, 114 Vasilissis Sofias Avenue, 11527 Athens, Greece
Konstantinos Tsioufis
First Department of Cardiology, Hippokration General Hospital, National and Kapodistrian University of Athens Medical School, 114 Vasilissis Sofias Avenue, 11527 Athens, Greece
Obesity and hypertension have become an international health issue, with detrimental consequences on patients. Obesity and hypertension share common pathophysiological mechanisms, such as overactivity of the renin–angiotensin–aldosterone and the sympathetic nervous systems, insulin resistance, and disruption of the leptin pathway. Approved therapies for obesity and overweight include phentermine/topiramate, orlistat, naltrexone/bupropion, the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide, tirzepatide, and bariatric surgery. This review gives the clinical data in a thorough manner and explains in detail how each of the previously mentioned therapies affects blood pressure levels.
